NNC0487-0111 for Weight Loss in Type 2 Diabetes
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Recruiting
Phase 3
Interventional Study
Diabetes Mellitus
Overweight
Obesity
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 630 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
Who this trial is looking for
This trial is looking for people who have excess weight and type 2 diabetes. Participants will receive either the study medication NNC0487-0111 or a placebo shot once a week, decided by chance.
Are You a Good Fit for This Trial?
You may be able to join if
- I am 18 years or older
- I have been diagnosed with type 2 diabetes for at least 180 days
- I have been treated with lifestyle changes and/or oral diabetes medications
- I have a blood sugar level (HbA1c) between 7% and 10%
You may not be able to join if
- I have severe kidney problems
- I have diabetic eye diseases that need treatment
- I do not feel symptoms of low blood sugar
- I have had severe low blood sugar episodes in the past year
- I have taken GLP-1 receptor agonists or similar treatments before
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment partici…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male or female (sex at birth).
* Age 18 years or above at the time of signing informed consent.
* Diagnosed with type 2 diabetes mellitus more than equal to (≥) 180 days before screening.
* Treatment with lifestyle intervention, and/or 0-3 marketed oral antidiabetic drugs (OAD…
Contacts